Meftal%25252525252525252525252525252525252525252525252520spas

# Meftal spas ## Overview Meftal spas is a combination product containing mefenamic acid, a nonsteroidal anti-inflammatory drug (NSAID), and dicyclomine hydrochloride, an anticholinergic antispasmodic agent. ## Primary Indications * Symptomatic relief of mild to moderate pain associated with: * Spasmodic abdominal pain * Colic * Menstrual pain (dysmenorrhea) ## Adult Dosing * **Mefenamic Acid:** 250 mg to 500 mg orally every 6 to 8 hours as needed. Do not exceed 1500 mg per day. * **Dicyclomine Hydrochloride:** 10 mg to 20 mg orally every 6 to 8 hours as needed. Do not exceed 80 mg per day. *Specific dosing for Meftal spas, if available as a fixed-dose combination, should follow product labeling. If not, doses should be managed individually.* ## Pediatric Dosing * Mefenamic acid: Generally not recommended in children under 14 years of age due to lack of established safety and efficacy. If used, dosing is typically 6.5 mg/kg orally every 6 hours, not to exceed 500 mg per dose or 1500 mg per day. * Dicyclomine hydrochloride: Safety and efficacy in children are not well established. Use with caution in children. Limited data suggests doses of 5 mg to 10 mg orally three to four times daily for children 2-12 years, but this is off-label. *Specific pediatric dosing for Meftal spas is not established. Use in pediatrics requires careful consideration and consultation.* ## Dose Adjustments * **Renal Impairment:** Use with caution. Mefenamic acid is renally excreted. Consider dose reduction or discontinuation in severe renal impairment. * **Hepatic Impairment:** Use with caution. Mefenamic acid can exacerbate liver dysfunction. * **Elderly:** Increased risk of adverse effects, particularly gastrointestinal bleeding, renal, and cardiovascular events. Use lowest effective dose for shortest duration. ## Contraindications * Hypersensitivity to mefenamic acid, dicyclomine, or any component of the formulation. * History of asthma, urticaria, or allergic-type reactions after aspirin or other NSAIDs. * Inflammatory bowel disease (e.g., ulcerative colitis, Crohn's disease). * Gastrointestinal obstruction, paralytic ileus. * Uncontrolled glaucoma. * Myasthenia gravis. * Infants less than 6 months of age (for dicyclomine). * Severe renal or hepatic impairment. * Severe heart failure. ## Adverse Effects * **Common:** Nausea, vomiting, diarrhea, constipation, abdominal pain, dizziness, headache, drowsiness. * **Serious:** * **Mefenamic Acid:** Gastrointestinal bleeding, ulceration, perforation; renal failure; hepatic failure; cardiovascular thrombotic events; hypersensitivity reactions (including Stevens-Johnson syndrome, exfoliative dermatitis); exacerbation of asthma. * **Dicyclomine:** Anticholinergic effects (dry mouth, blurred vision, urinary retention, constipation, confusion, tachycardia); paradoxical excitement in infants. ## Key Drug Interactions * **Mefenamic Acid:** * **Anticoagulants (e.g., warfarin):** Increased risk of bleeding. * **Corticosteroids:** Increased risk of gastrointestinal bleeding. * **Other NSAIDs:** Increased risk of gastrointestinal toxicity and other adverse effects. * **ACE inhibitors, ARBs, Diuretics:** Reduced antihypertensive effect, increased risk of renal impairment. * **Lithium:** Increased lithium levels. * **Dicyclomine:** * **Anticholinergics:** Additive anticholinergic effects. * **Amantadine:** Additive anticholinergic effects. * **MAO inhibitors:** May prolong or intensify anticholinergic effects. * **Opioids:** May increase risk of severe constipation and ileus. ## Monitoring * **GI Bleeding:** Monitor for signs and symptoms of bleeding (e.g., melena, hematemesis, abdominal pain). * **Renal Function:** Monitor BUN, creatinine, especially in patients with pre-existing renal disease or those at risk. * **Hepatic Function:** Monitor liver enzymes periodically, especially with long-term use or in patients with liver disease. * **Blood Pressure:** Monitor for increases, especially with NSAID use. * **Dicyclomine Effects:** Monitor for anticholinergic side effects. ## Clinical Pearls * Meftal spas should be used at the lowest effective dose for the shortest duration necessary to minimize risks, particularly gastrointestinal, renal, and cardiovascular adverse events associated with mefenamic acid. * Anticholinergic effects of dicyclomine can be dose-limiting and may be more pronounced in the elderly. * Avoid concomitant use with other NSAIDs. * Mefenamic acid should be taken with food or milk to reduce gastrointestinal upset. * This combination is not typically a first-line agent for chronic pain. *** **Disclaimer:** This information is for educational purposes only and does not substitute professional medical advice. Always consult with a qualified healthcare provider for any health concerns or before making any decisions related to your health or treatment. Verify current prescribing information from the manufacturer and relevant drug compendia before use.